Liveyon’s Live ‘Pure-Cast’ Podcast Series Sheds Light on Miseducation in Stem Cell Industry

For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

Liveyon Pure Cast

Manufacturer of Liveyon Pure® Launches Tool to Help Educate Public on the Facts, Fictions, and Future of Stem Cells and Regenerative Therapy

Liveyon Pure Cast Official Website

YORBA LINDA, Calif., March 29, 2019 – Industry leader Liveyon, LCC is taking on the most controversial topics in regenerative medicine with a new, live video podcast Liveyon Pure Cast, designed to spotlight the developing stem cell industry with an in-depth look at common misconceptions, scientific breakthroughs and advancements, and popular issues and concerns. A pioneer in the stem cell industry and manufacturer of the highly acclaimed Liveyon Pure® regenerative therapy umbilical cord stem cell product line, Liveyon sets itself apart within the highly competitive industry with its strong commitment to safety, education, and innovation.

To combat current misconceptions surrounding the field and solve the fact that most people cannot successfully discern between fact and fiction related to regenerative medicine and the use of stem cells, Liveyon launched Liveyon Pure Cast, a video podcast dedicated to bringing to light the truth about this emerging field and connecting doctors, researchers, patients, and the general public directly with well-respected industry leaders. Still an experimental industry, regenerative medicine has been flooded by ‘entrepreneurs’ riding the newest profit trend who are not focused on safety, research, or results; as shown by the increase in malpractice and fraud cases related to stem cell products and therapies. Without strict FDA regulation, the industry is in ‘self-policing’ mode, leaving doctors and patients with the difficult task of discerning between high-quality, effective products and services in the market and those that are either unsafe or ineffective.

The ‘Liveyon Pure Cast’ provides a complimentary resource for clients of the company’s new product line. On March Liveyon debuted Liveyon PURE® trial grade stem cell concentrate derived from umbilical cord blood. Used by physicians treating patients suffering from orthopedic pain and injuries, the stem cells found in the Liveyon PURE® Product may help regenerate bone, muscle, and cartilage and release a host of reparative growth factors and proteins. The innovative product is manufactured at Liveyon Labs, the company’s own FDA-registered and cGMP compliant facility and sets a new industry standard for characterization and consistency in live total nucleated cell counts, viability, purity and safety.

With its cutting edge live video streaming podcast format, available to view seamlessly on the Liveyon Pure Cast YouTube channel; the podcast provides a comprehensive look at the most controversial and most popular issues in regenerative medicine, including misconceptions, popular false claims, and concerns about lack of transparency in the industry. One of the show’s most important goals is to connect new research and educational resources to industry leaders, including health care providers and patients looking for truthful and up-to-date information about the industry.

The exclusive video series streams live every Monday, Wednesday and Friday morning and features John Kosolcharoen, founder and chief executive officer of Liveyon and Dr. Alan Gaveck, director of education, Liveyon. Dr. Gaveck brings 13 years of experience in both clinical and surgical medical treatments and the two hosts’ intellectual chemistry enhances the show’s format, as they tackle groundbreaking topics and introduce experts in the field of regenerative medicine, including leading researchers and physicians.

“The Liveyon Pure Cast provides an important new tool for patients, physicians, and the general public to navigate this complex and ever-changing industry,” said John Kosolcharoen, chief executive officer of Liveyon. “The connection, between the real facts, newest research, and groundbreaking scientific results; and both industry leaders and the general public; has been missing in the field of regenerative medicine until now, causing the growth of misleading rumors and information to thrive.”

Previous Liveyon Pure Cast series guests have included Dr. Rafael Gonzalez and Margaret Coutts, Ph.D., tackling the misconception that umbilical cord products don’t actually include live cells; Los Angeles’ top dermatologist, Dr. Ben Behnam MD, FAAD, who shared stem cell hair restoration success stories and identified the best candidates for hair regrowth; and Liveyon’s President of Sales, Joe Case, who provided information on Liveyon’s patient acquisition program for stem cell and regenerative medicine clinics and physicians.

“On the ‘Liveyon Pure Cast’ podcast we go in depth on every aspect of the field of regenerative medicine, providing important information to our current and future Liveyon PURE® customers and sharing facts the medical community and the general public need to make an informed decision on this important new field, which is about to change everything about how we look at healing,” said Kosolcharoen.

Focused on international growth in 2019, Liveyon is currently tacking the highly competitive markets of China and Central America by introducing its highly acclaimed Liveyon PURE® trial grade stem cell concentrate product. The company is looking to open new manufacturing labs in both countries and is currently filming a documentary titled “The Hope Cell, directed by James Buzzacco, capturing the story of their international growth.

Founded in 2016, Liveyon is pushing the boundaries of regenerative medicine with its innovative take on product research and development, manufacturing and distribution, and commitment to safety and transparency. Liveyon and Liveyon Labs Inc. are committed to achieving unparalleled stem cell potency through high live nucleated cell counts, while following validation protocols that produce an extremely consistent product for the most efficacious outcomes. The company’s dynamic ability to adapt to changing market trends and execute on opportunities has fortified its exponential growth and the company is poised to continue making a huge impact in the industry 2019.

“We welcome you to share this journey with us,” said Dr. Alan Gaveck, co-host, Liveyon Pure Cast. “The future of this dynamic new industry is here and the results Liveyon and other industry leaders in the regenerative medicine field are already achieving are going to change our world for the better. Each week, we are creating compelling educational and uniquely entertaining live stream broadcasts and delivering ‘in the now’ insight into cellular science and a regenerative medicine lifestyle.”

Host: John Kosolcharoen

Liveyon entered the marketplace in 2016 with the ultimate goal of pushing the existing boundaries of regenerative medicine in all aspects of product research/ development, and manufacturing/ distribution. Liveyon’s dynamic ability to adapt to changing market trends and execute on opportunities has allowed for the exponential growth of the company and has solidified the convictions of Liveyon’s CEO and founder John Kosolcharoen. Get up close and personal with him on the Liveyon Pure Cast podcast show.

Host: Dr. Alan Gaveck

There are many doctors wanting to practice regenerative medicine but have no access to the required training. Liveyon stands out as the industry leader in providing training andclinical protocols to follow. Whether you are brand new in the industry or a seasoned expert needing the latest trends and updates, Liveyon’s Director of Education, Dr. Alan Gaveck will make these programs available to you. Get to know how he operates on the Liveyon Pure Cast podcast show today.





Want to learn more about Liveyon Stem Cells? Contact us for more information.

Translate »


Medical Professional Viewing Only (Disclaimer)

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.